Login
uniQure NASDAQ: QURE
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands.
| Name | uniQure |
| Ticker | QURE |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Price | 37.53 |
| 52W Low/High | 35.35 / 67.74 |
| Market cap | 1.7 B |
| 1Y Total Return |
-44.42%
Weak |
| 1Y Volatility |
63.34%
Average Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands.
Details
| Ticker | QURE |
| Name | uniQure |
| ISIN | NL0010696654 |
| CUSIP | |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Country | Netherlands |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 1/15/21
| Close Price | 37.53 |
| 52W Low/High | 35.35 / 67.74 |
| Market cap | 1.7 B |
| 1Y Total Return |
-44.42%
Weak |
| 1Y Volatility |
63.34%
Average Risk |
| Beta | 1.81 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -2,738.3% |
| Cash from Op. / Cur. Liabilities | -3.71 |
| Diluted Earnings / Share | -3.77 |
| ROE | - |
| ROIC | -417.0% |
| Price / Revenue | 275.7 |
| Price / Book | 7.3 |
| Price / CF | -13.5 |
| Current Ratio | 8.6 |
| Cur.Liabilities / Tot.Liabilities | 0.3 |
| Financial Leverage | 0.31 |
| in Mils USD |
rolling-year up to September
|
|||||
|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
6
|
6
|
12
|
20
|
-
|
|
| Gross Profit |
6
|
6
|
12
|
20
|
-
|
|
| R&D |
117
|
87
|
74
|
74
|
-
|
|
| EBITDA |
-152
|
-94
|
-74
|
-56
|
-
|
|
| Operating Income |
-153
|
-114
|
-89
|
-80
|
-
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
|
| per Share | ||||||
| Diluted avg Shares |
44
|
41
|
37
|
26
|
-
|
|
| EPS exc. Extra |
-3.77
|
-2.74
|
-2.66
|
-2.61
|
-
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
351
|
472
|
281
|
139
|
-
|
|
| Cash, Eq & Invt ShortTerm |
279
|
403
|
240
|
89
|
-
|
|
| Total Current Assets |
287
|
408
|
242
|
92
|
-
|
|
| Total Non-Current Assets |
63
|
64
|
39
|
47
|
-
|
|
| Intangibles |
5
|
6
|
6
|
10
|
-
|
|
| Total Liabilities |
123
|
121
|
81
|
119
|
-
|
|
| Total Current Liabilities |
33
|
28
|
32
|
25
|
-
|
|
| Long Term Debt |
89
|
93
|
49
|
94
|
-
|
|
| Shareholder equity |
228
|
350
|
200
|
20
|
-
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
-124
|
-91
|
-76
|
-62
|
-
|
|
| Depreciation |
10
|
7
|
12
|
8
|
-
|
|
| Cash from Investing |
-9
|
-5
|
-5
|
-8
|
-
|
|
| Capex |
6
|
4
|
3
|
7
|
-
|
|
| Cash from Financing |
5
|
262
|
232
|
1
|
-
|
|
| Stock Issued |
5
|
248
|
231
|
1
|
-
|
|
| Debt (LT) Issued |
0
|
15
|
0
|
0
|
-
|
|
| Free Cash Flow |
-153
|
-100
|
-68
|
-
|
-
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
8.6
|
14.3
|
7.6
|
3.6
|
-
|
|
| Financial Leverage D/E |
0.31
|
0.20
|
0.10
|
1.05
|
-
|
|
| Return on Capital Avg |
-417.0%
|
-408.8%
|
-508.1%
|
-522.1%
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available